Specific, versatile, effective RNA-guided cell depletion
Total raised: $8.3M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.02.2025 | Seed | $8.3M | - |
Mentions in press and media 4
| Date | Title | Description |
| 05.02.2025 | Akribion Therapeutics: Pioneering Precision in Biotech with €8 Million Seed Funding | In the world of biotechnology, innovation is the lifeblood. Akribion Therapeutics, a fledgling biotech company based in Zwingenberg, Germany, has just taken a significant leap forward. With the announcement of an €8 million seed funding rou... |
| 04.02.2025 | Akribion secures €8M Seed to fight disease with genomics | German spinout Akribion Therapeutics, an RNA-focused biotech, has raised €8M to accelerate its therapeutic development. The round was led by CARMA FUND and RV Invest, with investments from MP Beteiligungs GmbH, Hessen Kapital I, Bruker Inve... |
| 04.02.2025 | BioTech startup Akribion Therapeutics raises €8 million to develop programmable cell depletion | Akribion Therapeutics, a Zwingenberg-based BioTech startup developing a RNA-guided, nuclease-based technology for programmable cell depletion, today announces its exit from stealth and the completion of a Seed financing round raising €8 mil... |
| 04.02.2025 | Akribion Therapeutics Raises €8M in Seed Financing | Akribion Therapeutics, a Zwingenberg, Germany-based early-stage biotech company developing a RNA-guided, nuclease-based technology for programmable cell depletion, raised €8M in Seed funding. The round was led by CARMA FUND and RV Invest wi... |